Issued 2026-08-13 at $49.50 · now $47.94 (2026-08-13, −3.2% since)
Based on its own history, a month from the 2026-08-13 close, TGTX has typically landed between $34.92 and $73.70 — a range of −29.5% to +48.9% from the issuance price $49.50.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,062 overlapping 1 month windows · 2010-05-03 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($49.50) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TGTX has typically landed a month from the 2026-08-13 close of $49.5 — the range is history, not a prediction.
- now $47.94 (-3.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $49.9 (+0.8%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $42.47–$57.32
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $34.92–$73.7
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2012-02-17 | −76.7% | −76.7% | +0.0% |
| 2012-02-10 | −75.0% | −75.0% | +7.5% |
| 2012-02-09 | −71.4% | −71.4% | +22.9% |
| 3 best | |||
| 2012-01-06 | +1891.2% | +0.0% | +1891.2% |
| 2012-01-05 | +1642.5% | +0.0% | +1642.5% |
| 2012-01-04 | +1517.7% | +0.0% | +1517.7% |
4,062 overlapping windows · 2010-05-03 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 3 primary completion: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) (source, as of 2026-08-14)
- 2027-05-30 — Trial primary completion: Phase 2 primary completion: A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) (source, as of 2026-08-14)
- 2027-12-01 — Trial primary completion: Phase 3 primary completion: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (source, as of 2026-08-14)
- 2028-07-01 — Trial primary completion: Phase 2 primary completion: A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) (source, as of 2026-08-14)
- 2028-12-01 — Trial primary completion: Phase 2 primary completion: Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia (source, as of 2026-08-14)
- 2030-01-01 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (source, as of 2026-08-14)
- 2032-05-31 — Trial primary completion: Phase 3 primary completion: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~17 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.